LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.
Read More…
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Phone44-0-20-3325-0660
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.11 billion
Profitability
Miscellaneous
Employees4,000
Next Earnings Date10/30/2019 (Estimated)
OptionableOptionable
LivaNova (NASDAQ:LIVN) Frequently Asked Questions
What is LivaNova's stock symbol?
LivaNova trades on the NASDAQ under the ticker symbol "LIVN."
How were LivaNova's earnings last quarter?
LivaNova PLC (NASDAQ:LIVN) issued its quarterly earnings data on Wednesday, July, 31st. The company reported $0.56 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.59 by $0.03. The firm had revenue of $277.20 million for the quarter, compared to analysts' expectations of $275.14 million. LivaNova had a negative net margin of 23.86% and a positive return on equity of 8.56%. The company's revenue for the quarter was down 3.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.96 EPS. View LivaNova's Earnings History.
When is LivaNova's next earnings date?
What guidance has LivaNova issued on next quarter's earnings?
LivaNova updated its FY19 earnings guidance on Wednesday, July, 31st. The company provided EPS guidance of $3.00-3.10 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.03. The company issued revenue guidance of +1-3% yr/yr to $1.2-1.4 billion, compared to the consensus revenue estimate of $1.11 billion.
What price target have analysts set for LIVN?
7 analysts have issued twelve-month price objectives for LivaNova's stock. Their predictions range from $90.00 to $150.00. On average, they anticipate LivaNova's stock price to reach $108.3333 in the next year. This suggests a possible upside of 38.0% from the stock's current price. View Analyst Price Targets for LivaNova.
What is the consensus analysts' recommendation for LivaNova?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LivaNova in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for LivaNova.
What are Wall Street analysts saying about LivaNova stock?
Here are some recent quotes from research analysts about LivaNova stock:
- 1. According to Zacks Investment Research, "LivaNova PLC is a medical technology company which focuses on providing treatment for cardiovascular diseases and neuromodulation. The Company's operating units consists of Cardiac Rhythm Management, Cardiac Surgery and Neuromodulation. LivaNova PLC, formerly known as Cyberonics, Inc., is based in London, United Kingdom. " (8/7/2019)
- 2. BTIG Research analysts commented, "As expected, LIVN revised down FY19 guidance following the pre- announcement. Although we had taken down estimates following the miss, the cut to the U.S. Neuromod outlook was still $10-20M worse than we expected. FY19 EPS is now expected to reach $3.00-3.10, ~$0.15 lower than our already lowered $3.21 forecast. Comps turn more difficult on the base business but with a fuller impact from Epidiolex going forward and no imminent relief in the lagging Heart valves business, we feel that even meeting the low end of the 1-3% constant currency guidance could prove challenging. Optics should improve in the back half when the TRD trial begins to enroll but even successful enrollment and reimbursement are not entirely certain. Overall, we think it will take a few quarters to regain credibility and enhance investor confidence in a turnaround in FY20." (5/2/2019)
- 3. Needham & Company LLC analysts commented, "LIVN beat consensus revenue and EPS in 4Q18. Management provided 2019 revenue growth guidance that was above consensus at the mid-point and adjusted EPS guidance that was below consensus due to treatment- resistant depression (TRD) investments (costing $0.15-0.20 of EPS). Organic revenue growth slowed to 7% in 4Q18 from 8% in 3Q18 given a tougher comp and weakness in Cardiovascular, slightly offset by strength in Neuromodulation. Gross margin was up 470 bps Y/Y while operating margin was up 80 bps Y/Y due to SG&A and R&D investments to fund current and future growth initiatives. While we expect LIVN’s reinvestment to weigh on its margins and EPS in the near-term, we believe it will drive faster revenue growth in future periods and we reiterate our Buy rating." (2/27/2019)
Has LivaNova been receiving favorable news coverage?
Media headlines about LIVN stock have trended somewhat negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. LivaNova earned a coverage optimism score of -1.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for LivaNova.
Are investors shorting LivaNova?
LivaNova saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 1,985,200 shares, an increase of 44.6% from the July 31st total of 1,373,100 shares. Based on an average daily trading volume, of 384,800 shares, the short-interest ratio is presently 5.2 days. Approximately 4.1% of the shares of the company are sold short. View LivaNova's Current Options Chain.
Who are some of LivaNova's key competitors?
Some companies that are related to LivaNova include SONOVA HLDG AG/ADR (SONVY), Varian Medical Systems (VAR), Masimo (MASI), GETINGE AB/ADR (GNGBY), CONMED (CNMD), Natus Medical (BABY), Natus Medical (NTUS), InMode (INMD), AxoGen (AXGN), TransMedics Group (TMDX), Cutera (CUTR), BioLife Solutions (BLFS), Viewray (VRAY), Zynex (ZYXI) and Semler Scientific (SMLR).
What other stocks do shareholders of LivaNova own?
Who are LivaNova's key executives?
LivaNova's management team includes the folowing people:
- Mr. Damien McDonald, CEO & Director (Age 54)
- Mr. Thad Huston, Chief Financial Officer (Age 49)
- Mr. Douglas J. Manko, Chief Accounting Officer (Age 45)
- Ms. Keyna Pidcock Skeffington, Gen. Counsel & Sr. VP (Age 56)
- Mr. David S. Wise, Sr. Advisor (Age 64)
Who are LivaNova's major shareholders?
LivaNova's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (12.08%), BlackRock Inc. (12.08%), Price T Rowe Associates Inc. MD (4.95%), Invesco Ltd. (4.75%), UBS Asset Management Americas Inc. (2.87%) and Wells Fargo & Company MN (2.73%). Company insiders that own LivaNova stock include Alfred J Novak, Alistair Simpson, Damien Mcdonald, Daniel Jeffrey Moore, David S Wise, Douglas John Manko, Francesco Bianchi, Hugh M Morrison, Thad Allen Huston and William A Kozy. View Institutional Ownership Trends for LivaNova.
Which institutional investors are selling LivaNova stock?
LIVN stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Point72 Asset Management L.P., Rhenman & Partners Asset Management AB, Canada Pension Plan Investment Board, Vaughan Nelson Investment Management L.P., JPMorgan Chase & Co., Rothschild & Co. Asset Management US Inc. and Bessemer Group Inc.. Company insiders that have sold LivaNova company stock in the last year include Alfred J Novak, Alistair Simpson, Damien Mcdonald, Daniel Jeffrey Moore, David S Wise, Hugh M Morrison and Thad Allen Huston. View Insider Buying and Selling for LivaNova.
Which institutional investors are buying LivaNova stock?
LIVN stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., Price T Rowe Associates Inc. MD, D. E. Shaw & Co. Inc., Primecap Management Co. CA, DekaBank Deutsche Girozentrale, UBS Asset Management Americas Inc., Nuveen Asset Management LLC and Bank of America Corp DE. View Insider Buying and Selling for LivaNova.
How do I buy shares of LivaNova?
Shares of LIVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is LivaNova's stock price today?
One share of LIVN stock can currently be purchased for approximately $78.53.
How big of a company is LivaNova?
LivaNova has a market capitalization of $3.80 billion and generates $1.11 billion in revenue each year. The company earns $-189,400,000.00 in net income (profit) each year or $3.17 on an earnings per share basis. LivaNova employs 4,000 workers across the globe.View Additional Information About LivaNova.
What is LivaNova's official website?
How can I contact LivaNova?
LivaNova's mailing address is 20 EASTBOURNE TERRACE, LONDON X0, W2 6LG. The company can be reached via phone at 44-0-20-3325-0660 or via email at [email protected]
MarketBeat Community Rating for LivaNova (NASDAQ LIVN)
MarketBeat's community ratings are surveys of what our community members think about LivaNova and other stocks. Vote "Outperform" if you believe LIVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LIVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
